ClinicalTrials.Veeva

Menu

HIV Testing & Womens Attitudes on HIV Vaccine Trials

Indiana University logo

Indiana University

Status and phase

Completed
Phase 3

Conditions

HIV

Treatments

Behavioral: Message Sidedness

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00771537
R01NR010004 (U.S. NIH Grant/Contract)
0601-09

Details and patient eligibility

About

The purpose of this study is to test the effects of different persuasive informational messages on rates of rapid HIV testing and willingness to participate in a HIV vaccine clinical trial. Adult African-American, non-Latina White, and Latina women will be recruited. Women will initially be randomized to 4 groups: 1. no message control; 2. 1-sided message that mentions benefits of HIV testing; 3. 2-sided message that acknowledges minor opposition to testing, then refutes the opposition; and 4. 2-sided message that acknowledge stronger opposition to testing, then refutes the opposition. Women will be offered HIV testing, then re-randomized to a similar set of 4 messages related to HIV vaccine trials. There will therefore be 16 groups in total (4 X 4).

Full description

This 5-year proposal responds to PAS-03-168, "Enrolling Women and Minorities in HIV/AIDS Research Trials." This study seeks to evaluate persuasive message interventions to increase HIV testing rates and improve acceptability of participation in a phase 3 HIV vaccine clinical trial among African-American, Latina, and White women. We plan to evaluate 1-sided messages, which mention only the benefits of an action, versus 2-sided messages, which mention negative aspects of the action, followed by positive counterarguments. The Health Belief Model, Inoculation and Attribution Theories will guide the research. Participants will be women attending urban community health clinics in Indianapolis, IN. Specific Aim 1 is to identify obstacles to HIV testing and to participation in a HIV vaccine clinical trial. This aim will be accomplished in years 1 and 2 through individual semi-structured interviews. We will analyze data via thematic content analysis and will use interview findings to assist in the development of measures and interventions employed in the intervention phase (years 3-5). Specific Aim 2 is to evaluate the effects of 2-sided versus 1-sided persuasive messages on rates of acceptance of rapid HIV testing. Demographic, behavioral, and attitudinal measures will be administered via audio computer-assisted self-interview (A-CASI). Participants will be randomized to the intervention groups via A-CASI as well. The outcome will be acceptance/rejection of free rapid HIV testing. This Aim will be evaluated via binary logistic regression. Specific Aim 3 is to evaluate the effects of 2-sided versus 1-sided messages on willingness to participate in phase 3 clinical trials for a preventive HIV vaccine. Participants will complete this 2nd A-CASI survey and will again be randomized to intervention groups. The outcome will be a scale measuring acceptability of clinical trial participation. This Aim will be evaluated via one-way Analysis of Variance. This study is relevant to public health in that the results may help us to understand how to improve enrollment of women and minorities into preventive HIV vaccine clinical trials and how to encourage women and minorities to get tested for HIV.

Enrollment

2,031 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female
  • 18 years of age or older
  • Able to understand English or Spanish
  • Able to give informed consent

Exclusion criteria

  • Not female
  • Under 18 years of age
  • Not able to understand English and Spanish
  • Unable to give informed consent

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Triple Blind

2,031 participants in 16 patient groups

Arm 1. Control PLUS Control
No Intervention group
Arm 2. Control PLUS 1-Sided
Experimental group
Description:
No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 3. Control PLUS 2-Sided Trivial
Experimental group
Description:
No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 4. Control PLUS 2-Sided Major
Experimental group
Description:
No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 5. 1-Sided PLUS Control
Experimental group
Description:
1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 6. 1-Sided PLUS 1-Sided
Experimental group
Description:
1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 7. 1-Sided PLUS 2-Sided Trivial
Experimental group
Description:
1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Aim 8. 1-Sided PLUS 2-Sided Major
Experimental group
Description:
1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 9. 2-Sided Trivial PLUS Control
Experimental group
Description:
2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 10. 2-Sided Trivial PLUS 1-Sided
Experimental group
Description:
2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial
Experimental group
Description:
2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 12. 2-Sided Trivial PLUS 2-Sided Major
Experimental group
Description:
2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 13. 2-Sided Major PLUS Control
Experimental group
Description:
2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 14. 2-Sided Major PLUS 1-Sided
Experimental group
Description:
2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 15. 2-Sided Major PLUS 2-Sided Trivial
Experimental group
Description:
2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness
Arm 16. 2-Sided Major PLUS 2-Sided Major
Experimental group
Description:
2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
Treatment:
Behavioral: Message Sidedness

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems